Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Progranulin signaling in bladder cancer

Funder: National Cancer Institute

Funding period
USD 1.6 M
Funding amount
Abstract
DESCRIPTION (provided by applicant): Bladder cancer is one of the most common cancer in the United States with 70,530 estimated cases and 14,680 estimated deaths in 2010. Regardless of the treatment modality, bladder cancer often recurs and metastasizes with very poor prognosis. Understanding the cellular and molecular mechanisms that regulate the biology of bladder cancer progression and invasion would be critical to develop new forms of treatments against this devastating disease. We have established that the growth factor progranulin plays a critical role in bladder cancer by regulating motility and invasion of malignant urothelial cells and demonstrated that progranulin acts as an autocrine growth factor. Moreover we have shown an increased expression of progranulin in invasive bladder tumors vis-?-vis normal bladder. Collectively, our results support the hypothesis that progranulin may play a critical role as an autocrine growth factor in the establishment and progression of bladder cancer. Despite the strong connections with growth control and cancer, progranulin's mode of action is still poorly characterized. We have discovered that the focal adhesion kinase Pyk2 is activated by progranulin and its expression is increased in bladder cancer tissues. Conversely, knockdown of progranulin inhibits motility and anchorage-independent growth of metastatic bladder cancer cells. This indicates that progranulin may play a key role in the invasive (high motility) phenotype. Using pull-down experiments and proteomics we have identified for the first time drebrin as a membrane protein interacting with progranulin. Drebrin is an actin- binding protein involved in cell adhesion, motility and calcium signaling. Thus, we hypothesize that drebrin might be part of a supramolecular complex involved in progranulin signaling. We will test our hypothesis and accomplish the objectives of this application through the following specific aims: [1] Determine the mechanisms of progranulin action in bladder cancer cells. [2] Investigate the function of drebrin, a novel progranulin interacting protein, in the regulation of motility and invasion of bladder cancer cells. [3] Characterize the in vivo roles of progranulin, Pyk2 and drebrin in bladder cancer formation and progression. The expected results will provide not only novel information toward a better understanding of the mechanisms that regulate tumor cell motility but will also provide invaluable insight into the role of the progranulin signaling pathway in regulating the transition to the invasive phenotype in urothelial neoplasia. Once characterized the role of the progranulin pathway in bladder cancer formation and progression, these studies will greatly contribute to the identification of novel targets for therapeutic intervention in bladder tumors. In addition, progranulin, Pyk2 and drebrin may prove as novel diagnostic and/or prognostic biomarkers for bladder tumors.
Similar projects All >
Sorted by: Start Date
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Epigenetic regulators of subtype plasticity in bladder cancer

Bladder Cancer Advocacy Network to John Robert Christin

USD 1,700
2020 - 2020
Project list item
Characterization of Nectin-4 expression in molecular subtypes of urothelial cancer and mechanisms of resistance to enfortumab vedotin

Bladder Cancer Advocacy Network to Carissa Ellen Chu

USD 1,700
2020 - 2020
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021

System

Categories
  • FOR (ANZSRC)

    0601 Biochemistry and Cell Biology

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    2.1 Biological and endogenous factors

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Basic Science